Glenmark Pharma launches Rufinamide Tablets

Glenmark Pharmaceuticals on Tuesday announced the launch of Rufinamide Tablets USP, 200 mg and 400 mg.
The tablets are a therapeutic equivalent of Banzel Tablets, 200 mg and 400 mg of Eisai Inc. Glenmark was one of the first ANDA applicants to submit a substantially complete ANDA for Rufinamide Tablets USP, 200 mg and 400 mg, with a paragraph IV certification and received final approval on 16 May 2016.
According to IQVIA sales data for the 12-month period ending April 2021, the Banzel Tablets achieved annual sales of approximately $285.3 million.
Commenting on the launch, Sanjeev Krishan, president of Glenmark North America said, We are very pleased to be one of the first generic companies in the US to offer lower cost alternative to Banzel Tablets, 200 mg and 400 mg. The launch is our commitment to provide quality and affordable healthcare to our markets for patients.

Related Keywords

Sanjeev Krishan ,Eisai Inc ,Glenmark Pharmaceuticals ,Glenmark Pharmaceuticals On ,Rufinamide Tablets ,Banzel Tablets ,Glenmark North America ,Capital Market ,Anticonvulsants ,Rufinamide ,Riazoles ,Glenmark ,Mg Cars ,Chemistry ,Companies ,Chemical Substances ,Generic Pharmaceuticals ,Biotechnology Amp Medical Research Nec ,Healthcare ,President ,Esearchled Pharmaceutical ,சஞ்சீவ் கிருஷன் ,ேசை இன்க் ,க்ளேண்மர்க் மருந்துகள் ,க்ளேண்மர்க் மருந்துகள் ஆன் ,மூலதனம் சந்தை ,குடியிருப்பாளர் ,